CABA أخبار الفوركس
Cabaletta Bio Says FDA Grants Orphan Drug Designation To CABA-201 To Treat Systemic Sclerosis
Biotechnology company Cabaletta Bio, Inc. (CABA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, for the treatment of systemic sclerosis (SSc).
RTTNews
|
927 منذ أيام
